{"nct_id":"NCT06926868","title":"A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","status":"RECRUITING","status_verified_date":"2025-10","start_date":"2025-09-11","start_date_type":"ACTUAL","primary_completion_date":"2028-03-13","primary_completion_date_type":"ESTIMATED","completion_date":"2030-05-15","completion_date_type":"ESTIMATED","phases":["PHASE2","PHASE3"],"tickers":["BMY"]}